2024-10-17T18:46:09-05:00 2023-12-31 953001179 WINDES INC 2050 MAIN ST STE 1300 IRVINE CA 92614 990 2023-01-01 208730839 LUNG CANCER FOUNDATION OF AMERICA LUNG 5073541361 7381 LA TIJERA BLVD 451663 LOS ANGELES CA 90045 JIM BARANSKI EXECUTIVE DIRECTOR 5073541361 2024-09-18 1 1 ELEANOR A LIVINGSTON CPA MST P00226461 9498529433 2024-09-18 2023 2024-10-15 13:58:12Z X JIM BARANSKI 7381 LA TIJERA BLVD 451663 LOS ANGELES CA 90045 2291930 0 X WWW.LCFAMERICA.ORG X 2007 MN LCFA'S MISSION IS THE IMPROVEMENT IN SURVIVORSHIP OF LUNG CANCER PATIENTS THROUGH THE FUNDING OF TRANSFORMATIVE SCIENCE. LUNG CANCER FOUNDATION OF AMERICA IS WORKING TO CHANGE THE PUBLIC PERCEPTION OF LUNG CANCER THROUGH EDUCATION AND PERSONAL STORIES ABOUT LUNG CANCER AND TO IMPROVE PATIENT OUTCOMES THROUGH FUNDING IMPACTFUL RESEARCH.WHILE RAISING FUNDS TO SUPPORT LUNG CANCER RESEARCH, LCFA WILL RAISE THE PUBLIC'S AWARENESS AND SERVE AS A RESOURCE FOR PATIENTS OR ANYONE SEEKING ANSWERS, HOPE, AND ACCESS TO UPDATED TREATMENT INFORMATION, SCIENTIFIC INVESTIGATION, AND CLINICAL TRIALS. 10 8 6 224 0 0 1591831 2248823 0 0 1203 16814 -52498 0 1540536 2265637 400000 200000 0 0 438975 557682 0 0 134394 709607 1096490 1548582 1854172 -8046 411465 1180746 1548034 323900 279723 856846 1268311 X LUNG CANCER FOUNDATION OF AMERICA (LCFA) IS WORKING TO CHANGE THE PUBLIC PERCEPTION OF LUNG CANCER THROUGH EDUCATION AND PERSONAL STORIES ABOUT LUNG CANCER AND TO IMPROVE PATIENT OUTCOMES THROUGH FUNDING IMPACTFUL RESEARCH. 0 0 808466 200000 RESEARCH GRANT & SCIENTIFIC ADVANCMENTS: RESEARCH GRANT: AWARDED A SIX-FIGURE LUNG CANCER RESEARCH GRANT TO A YOUNG INVESTIGATOR, FOCUSING ON EARLY DETECTION, TARGETED THERAPIES, AND IMMUNOTHERAPY. THIS GRANT, MADE POSSIBLE THROUGH GENEROUS PRIVATE DONATIONS, HAS LED TO GROUNDBREAKING DISCOVERIES IN LUNG CANCER TREATMENT.SCIENTIFIC ADVANCEMENTS: SUPPORTED RESEARCH THAT CONTRIBUTED TO SIGNIFICANT PROGRESS IN PERSONALIZED TREATMENT STRATEGIES, INCLUDING ADVANCEMENTS IN TARGETED THERAPIES AND IMMUNOTHERAPY FOR BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) . 755379 AWARENESS INITIATIVES, SPEAKERS BUREAU, & COLLABORATIVE PARTNERSHIPS: AWARENESS INITIATIVES: REACHED MILLIONS OF PEOPLE THROUGH COMPREHENSIVE AWARENESS-RAISING CAMPAIGNS, EDUCATING THE PUBLIC ABOUT LUNG CANCER RISK FACTORS, EARLY DETECTION, AND TREATMENT OPTIONS. SPEAKERS BUREAU: INDIVIDUALS WHO HAVE FIRSTHAND EXPERIENCE WITH LUNG CANCER SHARE THEIR STORIES TO RAISE AWARENESS, EDUCATE, AND INSPIRE OTHERS, PROVIDING A POWERFUL VOICE FOR PEOPLE LIVING WITH LUNG CANCER. COLLABORATIVE PARTNERSHIPS: STRENGTHENED PARTNERSHIPS WITH SISTER ORGANIZATIONS TO MAXIMIZE THE IMPACT OF RESEARCH FUNDING AND ADVOCACY EFFORTS. THROUGH THESE ACCOMPLISHMENTS, LCFA HAS CONTINUED TO MAKE SIGNIFICANT STRIDES IN IMPROVING LUNG CANCER OUTCOMES AND SUPPORTING THE LUNG CANCER COMMUNITY. 94542 COMMUNITY ENGAGEMENT: FOSTERED A SUPPORTIVE COMMUNITY FOR LUNG CANCER PATIENTS AND THEIR FAMILIES THROUGH EDUCATIONAL RESOURCES, SUPPORT PROGRAMS, AND ADVOCACY EFFORTS. 1658387 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 6 0 1 6 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR AK CA CO CT DE FL GA HI ID IL IN IA KS KY LA MN MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X GINA CRUZ 5073541361 7381 LA TIJERA BLVD 451663 LOS ANGELES CA 90045 JIM BARANSKI EXECUTIVE DIRECTOR 40.00 X X 196000 0 6702 KIM NORRIS PRESIDENT 40.00 X X 98000 0 6527 SUSAN MANDEL MD SECRETARY 10.00 X X 0 0 0 MARTA KAUFFMAN DIRECTOR 1.00 X 0 0 0 ROBERT FIGLIN MD FACP DIRECTOR 1.00 X 0 0 0 DAVID T LEVINSON DIRECTOR 1.00 X 0 0 0 MARTIN EDELMAN DIRECTOR 1.00 X 0 0 0 CAROLYN ZAINER DIRECTOR 1.00 X 0 0 0 MICHELLE SAYER DIRECTOR 1.00 X 0 0 0 TRISH COURY DIRECTOR 1.00 X 0 0 0 294000 0 13229 1 0 1 0 M&C COMMUNICATIONS 6464 S QUEBEC STREET 200 CENTENNIAL CO 80111 COMMUNICATION SERVICES 370625 OFFSCRIP MEDIA 64 FULTON STREET ROOM 700 NEW YORK NY 10038 SOCIAL MEDIA 149970 2 35158 2213665 31402 2248823 5675 5675 37432 26293 11139 11139 11139 2265637 11139 0 5675 X 200000 200000 307229 261145 15361 30723 208304 177059 10415 20830 4852 4124 243 485 37297 31702 1865 3730 36437 17383 5147 13907 956155 893517 9005 53633 1006 1006 11459 373 11086 2849 2849 55426 55426 15391 15391 137 137 7182 7182 OTHER EXPENSES 10448 1634 8814 1854172 1658387 61391 134394 645806 122241 295267 1333753 238284 92040 1389 0 1180746 1548034 48900 79723 275000 200000 323900 279723 X 51648 1064005 805198 204306 856846 1268311 1180746 1548034 411465 0 X 0 1 X 1 0 X 1005221 1431119 1297921 1591831 2248823 7574915 1005221 1431119 1297921 1591831 2248823 7574915 4447446 3127469 6302 1720 414 1203 5675 15314 7590229 0.41200 0.47270 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 2265637 0 2265637 0 2265637 1854172 0 1854172 0 1854172 PART X, LINE 2: FIN 48: THE FOUNDATION HAS RECEIVED TAX-EXEMPT STATUS FROM THE INTERNAL REVENUE SERVICE UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE FOUNDATION RECOGNIZES THE FINANCIAL STATEMENT BENEFIT OF TAX POSITIONS, SUCH AS ITS POSITION OF BEING TAX EXEMPT, ONLY AFTER DETERMINING THAT THE RELEVANT TAX AUTHORITY WOULD MORE LIKELY THAN NOT SUSTAIN THE POSITION FOLLOWING AN AUDIT. THE FOUNDATION IS SUBJECT TO POTENTIAL INCOME TAX AUDITS ON OPEN TAX YEARS BY ANY TAXING JURISDICTION IN WHICH IT OPERATES. THE STATUTE OF LIMITATIONS FOR FEDERAL AND STATE PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. 1 YOUNG INVESTIGATOR RESEARCH 1 200000 FMV PART I, LINE 2: DESCRIBE THE ORGANIZATION'S PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS IN THE UNITED STATES: GRANT RECIPIENTS MUST PROVIDE THE FOLLOWING INFORMATION FOR CONSIDERATION: - PLANNED SPECIFIC AIMS. - RATIONALE FOR THE PROJECT TOGETHER WITH BACKGROUND, SIGNIFICANCE AND INNOVATION OF PROPOSAL. - BRIEF STATEMENT OF THE OVERALL EXPERIMENTAL APPROACH. - BRIEF STATEMENT DESCRIBING THE CLINICAL CONTEXT IN WHICH THE BIOMARKER OR RESEARCH PROJECT WILL BE USED AND THE QUANTITATIVE PERFORMANCE THAT YOUR BIOMARKER SHOULD ACHIEVE TO SHOW CLINICAL UTILITY. - NIH BIOSKETCH OF THE APPLICANT(S) BUDGET, INCLUDING PERSONNEL, SUPPLIES, PUBLICATION COSTS, TRAVEL, CLINICAL TRIAL COSTS, ANIMAL COSTS. X X X X X 0 0 0 0 0 0 0 0 0 JIM BARANSKI EXECUTIVE DIRECTOR 186000 0 10000 0 0 0 0 0 6702 0 202702 0 0 0 JULIE LEVINSON SISTER OF BOARD MEMBER DAVID T. LEVINSON. 18000 FREELANCE COPYWRITER 0 X 1 31402 SELLING PRICE 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B DESCRIBE THE PROCESS USED BY THE ORGANIZATION TO REVIEW THIS FORM 990: THE DRAFT FORM 990 IS REVIEWED BY THE LCFA CORPORATE OFFICERS, AND THEN SUBMITTED TO THE LCFA BOARD OF DIRECTORS FOR REVIEW AND COMMENT. FORM 990, PART VI, SECTION B, LINE 12C DID THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITOR THE CONFLICT OF INTEREST POLICY? LCFA'S CONFLICT OF INTEREST POLICY IS REVIEWED ANNUALLY AND EACH DIRECTOR, OFFICER AND SENIOR STAFF MEMBER WILL CERTIFY ANNUALLY THAT HE OR SHE HAS RECEIVED, READ, UNDERSTOOD AND IS IN COMPLIANCE WITH, THE POLICY. IT IS THE RESPONSIBILITY OF EACH OFFICER AND DIRECTOR OF THE CORPORATION TO DISCHARGE HIS OR HER DUTIES AS A DIRECTOR AND OFFICER IN GOOD FAITH, IN A MANNER THE PERSON REASONABLY BELIEVES TO BE IN THE BEST INTERESTS OF THE CORPORATION, AND WITH THE CARE AN ORDINARILY PRUDENT PERSON IN A LIKE POSITION WOULD EXERCISE UNDER SIMILAR CIRCUMSTANCES. FORM 990, PART VI, SECTION B, LINE 15 DID THE PROCESS TO DETERMINE COMPENSATION INCLUDE A REVIEW AND APPROVAL BY INDEPENDENT PERSONS, COMPARABLE DATA AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION? LCFA IS REGULARLY AND CONSISTENTLY MONITORING THE PERFORMANCE AND SALARY OF THE EXECUTIVE DIRECTOR, OTHER OFFICERS, AND KEY EMPLOYEES. LCFA UTILIZED A COMPENSATION STUDY AND A COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 DESCRIBE HOW THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMETNS AVAILABLE TO THE PUBLIC: LCFA MAKES ALL GOVERNING DOCUMENTS AND FINANCIAL INFORMATION AVAILABLE TO THE PUBLIC ON REQUEST. FORM 990, PART IX, LINE 11G EDUCATION AWARENESS: PROGRAM SERVICE EXPENSES 643,467. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 643,467. PATIENT EDUCATION: PROGRAM SERVICE EXPENSES 94,542. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 94,542. SPEAKERS BUREAU: PROGRAM SERVICE EXPENSES 111,912. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 111,912. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 5,644. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 22,976. TOTAL EXPENSES 28,620. PROFESSIONAL COMPLIANCE FEES: PROGRAM SERVICE EXPENSES 37,952. MANAGEMENT AND GENERAL EXPENSES 9,005. FUNDRAISING EXPENSES 30,657. TOTAL EXPENSES 77,614.